...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Oncology >21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer
【24h】

21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer

机译：21基因复发评分分析无法预测T1-2 N1mic ER阳性HER2阴性乳腺癌的乳房切除术后放疗的益处

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: It is still controversial whether post-mastectomy radiotherapy (PMRT) is necessary for women with T1-2 N1mic ER-positive HER2-negative breast cancer. The 21-gene recurrence score (RS) assay has been validated in T1-2 N1 breast cancer to be prognostic of locoregional recurrence (LRR) and overall survival (OS). This study aims to evaluate the predict value of 21-gene recurrence score assay for the benefit of PMRT in T1-2 N1mic ER-positive HER2-negative breast cancer. Methods: A population-based cohort study was performed on women with T1-2 N1mic ER-positive HER2-negative breast cancer who underwent mastectomy and were evaluated using the 21-gene RS in the Surveillance, Epidemiology, and End Results (SEER) registry between 2004 and 2015. Clinical characteristics as well as OS and breast cancer-specific survival (BCSS) were compared between patients with and without PMRT in patients with a Low-, Intermediate-, and High-RS. Multivariate COX regression analysis was performed to investigate if the 21-gene RS assay could predict benefit of PMRT in this group of breast cancer patients. Results: A total of 1571 patients met the criteria of our study and were enrolled, including 970 patients in the Low-Risk group (score &18), 508 in the Intermediate-Risk group (score 18–30), and 93 patients in the High-Risk group (score &30). In the High-Risk group, there were more patients with age ≥50 (87.0 vs. 64.3%, P = 0.040) and received chemotherapy with a borderline significance (91.3 vs. 72.9%, P = 0.066) in the PMRT subgroup than in the no PMRT subgroup. In all three groups, OS was comparable between the PMRT subgroup and the no PMRT subgroup. Furthermore, multivariate analysis did not show any OS benefit for PMRT based on the 21-gene recurrence score. Conclusion: This study showed that the 21-gene RS assay was not able to predict the benefit of PMRT for OS in women with T1-2 N1mic ER-positive HER2-negative breast cancer. However, further prospective larger sample-size trials are warranted to determine if a benefit exists.
机译：简介：对于T1-2 N1mic ER阳性HER2阴性乳腺癌的妇女是否必须进行乳房切除术后放疗（PMRT）仍存在争议。已在T1-2 N1乳腺癌中验证了21基因复发评分（RS）分析可预测局部复发（LRR）和总体生存（OS）。本研究旨在评估21基因复发评分分析对PMRT在T1-2 N1mic ER阳性HER2阴性乳腺癌中的益处的预测价值。方法：一项基于人群的队列研究对接受乳腺切除术的T1-2 N1mic ER阳性HER2阴性乳腺癌妇女进行了评估，并使用21基因RS进行了监测，流行病学和最终结果（SEER）登记在2004年至2015年之间。比较了具有低RS，中度和高RS的患者中有无PMRT的患者的临床特征以及OS和乳腺癌特异性生存率（BCSS）。进行了多变量COX回归分析，以调查21基因RS检测是否可以预测该组乳腺癌患者PMRT的获益。结果：共有1571名患者符合我们的研究标准，并入组，其中低风险组970名患者（得分＜18），中级风险组508名患者（得分18-30）和93名患者在高风险组中（得分> 30）。在高风险组中，PMRT亚组中≥50岁（≥87.0 vs. 64.3％，P = 0.040）接受边缘治疗的化疗患者（91.3 vs. 72.9％，P = 0.066）更多。没有PMRT子组。在所有三个组中，PMRT子组与无PMRT子组之间的OS相当。此外，基于21个基因的复发评分，多变量分析未显示PMRT有任何OS获益。结论：这项研究表明21基因的RS检测不能预测PMRT对T1-2 N1mic ER阳性HER2阴性乳腺癌女性的OS益处。但是，有必要进行进一步的前瞻性更大样本量试验来确定是否存在益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号